News
XVIPF
19.15
NaN%
--
Xvivo Perfusion Earnings Call Highlights Growth And Margins
TipRanks · 4d ago
XVIVO Perfusion AGM Backs Incentive Plan, Withholds Dividend and Expands Financing Flexibility
TipRanks · 4d ago
Xvivo Perfusion AB (publ) GAAP EPS of SEK1.15, revenue of SEK241M
Seeking Alpha · 04/24 11:30
Xvivo Perfusion Delivers Strong Q1 Growth and Advances Heart Preservation Trials
TipRanks · 04/24 06:07
XVIVO Reports Strong Early Trial Results for HOPE Technology in DCD Heart Transplants
TipRanks · 04/22 20:02
XVIVO’s U.S. PRESERVE Trial Shows Strong One-Year Outcomes for Heart Preservation Technology
TipRanks · 04/22 19:32
XVIVO Sets April 24 Call to Present Q1 2026 Interim Report
TipRanks · 04/17 12:05
XVIVO’s Heart Preservation Trial Shows Improved One‑Year Outcomes in European Study
TipRanks · 04/16 14:01
Xvivo Perfusion announces publication of one-year results from NIHP2019 trial
TipRanks · 04/16 13:09
Xvivo Perfusion AB (publ) GAAP EPS of SEK 0.80, revenue of SEK 812.2M
Seeking Alpha · 04/02 12:41
XVIVO Perfusion Calls 2026 AGM, Proposes New Board Members and Incentive Plan
TipRanks · 03/19 12:05
XVIVO Perfusion Updates Board Proposals Ahead of 2026 AGM
TipRanks · 02/20 13:32
XVIVO Perfusion nominates experienced healthcare leaders to strengthen board
TipRanks · 02/20 13:31
XVIVO Elevates CFO to Lead Global Strategy as It Targets U.S. Growth
TipRanks · 02/19 16:03
XVIVO Delays Q1 2026 Report to Spotlight Key U.S. Heart Study
TipRanks · 02/10 14:46
XVIVO Perfusion Balances Organ Business Growth With Heavy R&D Spend in 2025
TipRanks · 01/27 07:02
XVIVO Schedules Conference Call for 2025 Year-End Results
TipRanks · 01/15 14:36
XVIVO CEO to Spotlight Organ-Transplant Technology at J.P. Morgan Healthcare Conference
TipRanks · 01/06 14:07
XVIVO Perfusion’s Heart Preservation Study: A Potential Game-Changer for Transplants
TipRanks · 10/27/2025 22:16
Xvivo Perfusion AB’s DeLIVER Trial: A Promising Step in Liver Transplantation
TipRanks · 10/27/2025 17:40
More
Webull provides a variety of real-time XVIPF stock news. You can receive the latest news about Xvivo Perfusion through multiple platforms. This information may help you make smarter investment decisions.
About XVIPF
Xvivo Perfusion AB is a Sweden-based medical technology company focused on developing optimized solutions for organ, tissue and cell preservation in connection with transplantation. The Company operates in two segments: Durable goods and Non-Durable goods. The Durable goods segment comprises sale and rental income from XVIVO Perfusion System (XPS) machines. The Non-Durable goods segment implies revenue from the sale of products and services that are solutions and disposable items. The Company’s product portfolio consists of Perfadex, STEEN Solution, XPS, XPS Disposable Kit, XVIVO Lung Cannula Set, XVIVO Organ Chamber, XPS PGM Disposable Sensors and Silicone Tubing Set. The Company markets its products in Europe, Asia, Middle East, and North & South America.